WEDNESDAY, December 10th

Program: Poster Session 1, #P1-12-01
Session: Treatment: Adjuvant Endocrine Therapy
Trial: NCIC CTG MAC.5
Abstract: CYP19A1 and ESR1 polymorphisms and selected early-onset side effects during combined endocrine therapy in the IBCSG TEXT trial for premenopausal women with hormone receptor-positive (HR+) early breast cancer
Time: 5:00 PM-7:00 PM

THURSDAY, December 11th

Program: Poster Session 2, #P2-05-05
Session: Treatment: Molecular Profiles
Trial: NCIC CTG MA.5
Abstract: A four gene signature predicts anthracycline benefit: Evidence from the BR9601 and MAS breast cancer trials
Authors: Spears M, Lyttle NS, Yousif F, Munro AF, Twelves C, Pritchard KI, Levine MN, Shepherd L, Bartlett JMS
Time: 7:30 AM-9:00 AM

Program: Poster Session 3, #P3-09-02
Session: Treatment: Adjuvant Chemotherapy
Trial: NCIC CTG Breast Cancer Studies
Abstract: Association between definitive surgery and times to administration of adjuvant chemotherapy and outcomes in early breast cancer: Analysis of adjuvant studies conducted by NCIC Clinical Trials Group (NCIC CTG)
Authors: Ramjeesingh R, Chen BE, Pater JL, Zhu L, Burnell M, Bramwell VH, Pritchard KI, Shepherd LE, Parulekar WR.
Time: 5:00 – 7:00 PM
FRIDAY, December 12th

Program: Poster Session 4, #P4-11-06
Session: Prognostic Factors - Clinical Testing and Validation
Trial: NCIC CTG MA.21
Abstract: **TLE3 is not a predictive biomarker for taxane sensitivity in the NCIC CTG MA.21 clinical trial**
Authors: Bartlett JMS, Nielsen TO, Gao D, Gelmon KA, Quintayo MA, Starczynski J, Han L, Burnell MJ, Levine MN, Shepherd LE, Chapman J-AW.
Time: 7:30 - 9:00 AM

Program: Poster Session 4, #P4-11-11
Session: Prognostic Factors - Clinical Testing and Validation
Trial: NCIC CTG MA. 12
Abstract: **CADER prognostic gene signature for disease free survival in hormone receptor positive breast cancer: NCIC CTG MA.12 phase III placebo-controlled tamoxifen trial**
Time: 7:30 - 9:00 AM

Program: Poster Session 5, #P5-19-18
Session: Advanced Therapy - Targeted
Trial: NCIC CTG IND.197
Abstract: **A phase II study of Foretinib for triple negative metastatic breast cancer: NCIC CTG IND 197**
Time: 5:00 – 7:00 PM

Saturday, December 13th

Program: Poster Session 6, #P6-01-10
Session: Biomarkers
Trial: NCIC CTG MA.14
Abstract: **Prognostic significance of breast cancer index (BCI) in node-positive hormone receptor positive early breast cancer: NCIC CTG MA.14**
Time: 7:30 - 9:00 AM